A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01253057|
Recruitment Status : Unknown
Verified December 2010 by Taipei Medical University WanFang Hospital.
Recruitment status was: Active, not recruiting
First Posted : December 3, 2010
Last Update Posted : December 3, 2010
Several epidemiological studies found that exposure to antineoplastic agents were associated with some reproductive, carcinogenic effects, higher rates of advance micronuclei (MN), sister-chromatic-exchange (SCE) and spontaneous abortion. Cleaning staff were potentially exposed to these agents while cleaning ward, ward toilet or other area.
One medical center and one area hospitals in Taipei.Surface wipe samples were collected in the cleaning staff work area, such as ward environment and ward toilet. Urine and blood samples of subjects were collected for exposure examinations. Platinum-containing drugs (Cisplatin, Carboplatin, Oxaliplatin) were used as indicator drugs in environmental (surface wipe samples) and biological (urine and blood samples) samples.
A self-administered questionnaire was used to collect demographic data, working practices, medical and contact history, and perceived work-related symptoms of cleaning staff.
The results of this study will be to reduce exposure to cleaning staff.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure|
|Study Start Date :||October 2010|
|Estimated Study Completion Date :||December 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01253057
|Taipei Medical University WanFang Hospital|
|Principal Investigator:||Ruey-Yu Chen||Taipei Medical University|